Product logins

Find logins to all Clarivate products below.


The TreatmentTrends: Rheumatoid Arthritis 2014 (EU) report explores the treatment dynamics among more than 200 French, German, Italian, Spanish, and UK rheumatologists through comprehensive primary research methods and how these have evolved in recent years. The use of biologic products prescribed for rheumatoid arthritis is covered in particular detail. The report explores rheumatologists’ awareness, trial, and usage of currently available brands, as well as familiarity with and interest in key emerging therapies.

Related Market Assessment Reports

Report
Rheumatoid Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Rheumatoid Arthritis (US)
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Report
Rheumatoid Arthritis – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key rheumatoid arthritis patient populations, covering 171 countries and…
Report
Rheumatoid Arthritis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…
Report
Rheumatoid Arthritis – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the total and diagnosed…
Report
Rheumatoid Arthritis – Current Treatment – Current Treatment: Physician Insights – Rheumatoid Arthritis (EU5)
Many established therapies are available to treat rheumatoid arthritis (RA). Tumor necrosis factor-alpha (TNF-alpha) inhibitors are the most widely used class of agents after conventional disease-…